Paroxetine
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1992
- First approval year
- 1992
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Paroxetine
- Molecular weight
- 329.37
- Structure (SMILES)
- Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1
- (-)-(3S,4R)-4-(P-FLUOROPHENYL)-3-((3,4-METHYLENEDIOXY)PHENOXY)METHYL)PIPERIDINE
- (-)-TRANS-4-(P-FLUOROPHENYL)-3-((3,4-(METHYLENEDIOXY)PHENOXY)METHYL)PIPERIDINE
- (-)3s,4r-paroxetine
- 3s 4r 4 p fluorophenyl 3 3 4 methylenedioxy phenoxy methyl piperidine
- 3s 4r paroxetine
- arketis
- Arketis
- arotin
- Arotin
- besitram
- Besitram
- brl 29060
- BRL 29060
- BRL-29060
- casbol
- Casbol
- daparox
- Daparox
- fg 7051
- Fg-7051
- frosinor
- Frosinor
- motivan
- Motivan
- parogen
And 22 more, listed on the interactive page.
- ATC classification codes
- N06AB05
Sources for recorded values
- CAS registry numbers
- 61869-08-7
- ChEMBL ID
- CHEMBL490
- InChIKey
- AHOUBRCZNHFOSL-YOEHRIQHSA-N
- PubChem compound IDs
- 43815
- FDA ingredient codes (UNII)
- 41VRH5220H
- 32937
- 235830
- Applicant
- APOTEX
- Approval date
- 29 Dec 1992
- Application number
- NDA020031
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- Boxed warning
- Yes
- United States (FDA)
- Approved
- Pharmacology name
- paroxetine
- Type
- Synthetic organic
- Drug name stem
- -oxetine
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Action
- Antagonist
- Action type
- Antagonist
- Target
- P2X4
- Gene symbol
- P2RX4
- Protein identifier
- Q99571
- Affinity units
- pIC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- SERT
- Gene symbol
- SLC6A4
- Protein identifier
- P31645
- Median affinity
- 10.1
- Affinity units
- pKd
- Primary target
- Yes
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- SERT
- Gene symbol
- SLC6A4
- Protein identifier
- P31645
- Median affinity
- 9.6
- Affinity units
- pKi
- Primary target
- Yes
Open Targets mechanisms
- Mechanism
- Serotonin transporter inhibitor
- Action type
- Inhibitor
- Target
- Sodium-dependent serotonin transporter
DrugCentral mechanisms
- Action type
- Inhibitor
- Gene symbol
- SLC6A4
- Protein identifier
- P31645
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Myocardial Infarction
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000612
- Subject identifier
- D009203
- Condition
- Arthritis, Rheumatoid
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000685
- Subject identifier
- D001172
- Condition
- Idiopathic Pulmonary Fibrosis
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000768
- Subject identifier
- D054990
- Condition
- Stress Disorders, Post-Traumatic
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001358
- Subject identifier
- D013313
- Condition
- Depressive Disorder, Major
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003761
- Subject identifier
- D003865
- Condition
- Hepatitis C, Chronic
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004220
- Subject identifier
- D019698
- Condition
- Obsessive-Compulsive Disorder
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004242
- Subject identifier
- D009771
- Condition
- Panic Disorder
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004262
- Subject identifier
- D016584
- Condition
- Anxiety
- Highest recorded phase
- 3
- Condition identifier
- EFO:0005230
- Subject identifier
- D001007
- Condition
- Fibromyalgia
- Highest recorded phase
- 1
- Condition identifier
- EFO:0005687
- Subject identifier
- D005356
- Condition
- Neuralgia
- Highest recorded phase
- 3
- Condition identifier
- EFO:0005762
- Subject identifier
- D009437
- Condition
- Premature Ejaculation
- Highest recorded phase
- 3
- Condition identifier
- EFO:0803321
- Subject identifier
- D061686
- Condition
- Agoraphobia
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001872
- Subject identifier
- D000379
- Condition
- Anxiety Disorders
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001892
- Subject identifier
- D001008
- Condition
- Phobia, Social
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001917
- Subject identifier
- D000072861
- Condition
- Tinnitus
- Highest recorded phase
- 2
- Condition identifier
- HP:0000360
- Subject identifier
- D014012
- Condition
- Dementia
- Highest recorded phase
- 3
- Condition identifier
- HP:0000726
- Subject identifier
- D003704
- Condition
- Depressive Disorder, Major
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0002009
- Subject identifier
- D003865
- Condition
- Depressive Disorder
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0002009
- Subject identifier
- D003866
- Condition
- Depressive Disorder
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0002050
- Subject identifier
- D003866
- Condition
- Anovulation
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0002775
- Subject identifier
- D000858
- Condition
- Bipolar Disorder
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0004985
- Subject identifier
- D001714
- Condition
- Schizophrenia
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0005090
- Subject identifier
- D012559
- Condition
- Diabetes Mellitus, Type 2
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0005148
- Subject identifier
- D003924
- Condition
- Parkinson Disease
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0005180
- Subject identifier
- D010300
And 1 more, listed on the interactive page.
- Condition identifier
- EFO_0000612
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000677
- Condition identifier
- EFO_0000685
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001358
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003768
- Condition identifier
- EFO_0004220
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004242
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004262
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004320
- Condition identifier
- EFO_0005762
- Highest recorded phase
- 3
- Condition identifier
- EFO_0006834
- Highest recorded phase
- 2
- Condition identifier
- EFO_0007948
- Highest recorded phase
- 1
- Condition identifier
- EFO_0009842
- Highest recorded phase
- 1
- Condition identifier
- EFO_0009844
- Condition identifier
- EFO_0803536
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001892
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001917
- Highest recorded phase
- 3
- Condition identifier
- HP_0000360
- Highest recorded phase
- 2
- Condition identifier
- HP_0000739
- Condition identifier
- HP_0000739
- Highest recorded phase
- 2
- Condition identifier
- HP_0002360
- Condition identifier
- HP_0031217
- Condition identifier
- HP_0100543
- Condition identifier
- MONDO_0001247
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0001780
- Highest recorded phase
- 3
And 25 more, listed on the interactive page.
Open Targets warnings
- Warning
- Black Box Warning
- Effect
- psychiatric toxicity
- Country
- United States
- Event
- abnormal behaviour
- Reports
- 105
- Reporting signal score
- 96.1452
- Event
- abnormal dreams
- Reports
- 76
- Reporting signal score
- 103.672
- Event
- aggression
- Reports
- 351
- Reporting signal score
- 629.857
- Event
- agitation
- Reports
- 464
- Reporting signal score
- 740.375
- Event
- agoraphobia
- Reports
- 47
- Reporting signal score
- 182.31
- Event
- anger
- Reports
- 162
- Reporting signal score
- 290.475
- Event
- anxiety
- Reports
- 592
- Reporting signal score
- 663.359
- Event
- atrial septal defect
- Reports
- 155
- Reporting signal score
- 355.1
- Event
- bradykinesia
- Reports
- 50
- Reporting signal score
- 100.7
- Event
- bradyphrenia
- Reports
- 91
- Reporting signal score
- 201.56
- Event
- clonus
- Reports
- 47
- Reporting signal score
- 107.085
- Event
- coarctation of the aorta
- Reports
- 32
- Reporting signal score
- 95.4863
- Event
- coma
- Reports
- 204
- Reporting signal score
- 255.528
- Event
- completed suicide
- Reports
- 36
- Reporting signal score
- 119.978
- Event
- confusional state
- Reports
- 538
- Reporting signal score
- 626.244
- Event
- congenital anomaly
- Reports
- 56
- Reporting signal score
- 104.125
- Event
- crying
- Reports
- 94
- Reporting signal score
- 119.555
- Event
- depersonalisation
- Reports
- 31
- Reporting signal score
- 98.7356
- Event
- depressed mood
- Reports
- 211
- Reporting signal score
- 340.178
- Event
- depression
- Reports
- 435
- Reporting signal score
- 378.859
- Event
- disorientation
- Reports
- 155
- Reporting signal score
- 180.84
- Event
- dissociation
- Reports
- 57
- Reporting signal score
- 140.509
- Event
- disturbance in attention
- Reports
- 265
- Reporting signal score
- 459.411
- Event
- dizziness
- Reports
- 492
- Reporting signal score
- 157.189
- Event
- drug abuse
- Reports
- 474
- Reporting signal score
- 853.821
And 43 more, listed on the interactive page.
- NCT00000368
- NCT00195598
- NCT03199625
- NCT00048204
- NCT00049972
- NCT00067444
- NCT00073203
- NCT00351910
- NCT00368303
- NCT00400088
- NCT00445679
- NCT00463242
- NCT00489775
- NCT00629551
- NCT00742573
- NCT00744406
- NCT00825019
- NCT00825058
- NCT00926835
- NCT01254305
- NCT01360866
- NCT01416220
- NCT01460212
- NCT01608295
- NCT01764867
And 53 more, listed on the interactive page.
- Dose
- 20 mg
- Route
- Oral
- How often
- Once daily
Conditions of use
- Take with or without food
- Hydrogen bond acceptors
- 4
- Hydrogen bond donors
- 1
- Polar surface area
- 39.72
- Calculated partition coefficient (ALogP)
- 3.33
- Calculated partition coefficient (XLogP)
- 3.5
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 4
- Heavy atoms
- 24
- Molecular formula
- C19H20FNO3
- Monoisotopic mass
- 329.14272166
- Natural product
- No
- Recorded assays
- 2,543
- Active assays
- 289
- Confirmatory
- Other
- Screening
- Summary
- Selective Serotonin Reuptake Inhibitors
- Antidepressive Agents, Second-Generation
- Cytochrome P-450 CYP2D6 Inhibitors
These details could not be displayed.
Related records
Trials (178)
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)
- A 6 Week Study to Determine the Effectiveness of R228060 in Adult Subjects With Major Depressive Disorder
- A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- A Combination Therapy In Patients With Social Anxiety Disorder
- A Drug Interaction Study of 31001074 and Paroxetine in Healthy Volunteers
- A Local Register Study For Major Depression Of Paroxetine Controlled Release
- A Phase 1, Drug Interaction Study Between AVP-786 and Paroxetine and Between AVP-786 and Duloxetine in Healthy Subjects
- A Phase I Study of NS-079 in Healthy Participants
- A Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD)
- A Placebo-Controlled Study to Investigate the Onset of Action of Paroxetine in Premenstrual Dysphoria
- A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity
- A Repeat Dose Pharmacokinetic Study Of Paroxetine CR Tablet In Healthy Chinese Subjects
- A Single-Blind Trial of Risperidone vs. Paroxetine for Treatment of Panic Attacks
- A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression
- A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats
- A Study Of A New Medicine (GW597599B) For The Treatment Of Major Depressive Disorder
- A Study Of A New Medicine (GW679769) For The Treatment Of Social Anxiety Disorder
- A Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder
Approved for (2)
In development for (27)
- Agoraphobia Phase 3
- Alcohol dependence Phase 3
- Anovulation Phase 1
- Anxiety Phase 3
- Bipolar disorder Phase 3
- Breast cancer Phase 3
- Burning mouth syndrome Phase 3
- Chronic hepatitis C virus infection Phase 3
- Dementia Phase 3
- Fibromyalgia Phase 1
- Generalized anxiety disorder Phase 3
- Hearing loss disorder Phase 2
- Hepatitis C virus infection Phase 2
- Idiopathic pulmonary fibrosis Phase 1
- Multiple sclerosis Phase 3
- Myocardial infarction Phase 2
- Neuralgia Phase 3
- Obsessive-compulsive disorder Phase 3
- Panic disorder Phase 3
- Parkinson disease Phase 3
Other linked conditions (5)
- Anxiety disorder
- Cardiovascular disorder
- Eating disorder
- Mental disorder
- Nicotine dependence